{"id":59086,"date":"2026-03-09T13:11:26","date_gmt":"2026-03-09T05:11:26","guid":{"rendered":"https:\/\/flcube.com\/?p=59086"},"modified":"2026-03-09T13:11:27","modified_gmt":"2026-03-09T05:11:27","slug":"leads-biolabs-opamtistomig-enters-phase-ii-in-first-line-esophageal-cancer-pd-l1-4-1bb-bispecific-with-btd-odd-designations","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59086","title":{"rendered":"Leads Biolabs&#8217; Opamtistomig Enters Phase II in First-Line Esophageal Cancer \u2013 PD-L1\/4-1BB Bispecific with BTD\/ODD Designations"},"content":{"rendered":"\n<p><strong>Nanjing Leads Biolabs Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9887:HKG\">HKG: 9887<\/a>) announced <strong>first patient enrollment<\/strong> in a <strong>Phase II clinical study<\/strong> evaluating <strong>opamtistomig (LBL-024)<\/strong>, a <strong>bispecific antibody (BsAb) targeting PD-L1 and 4-1BB<\/strong>, in <strong>first-line esophageal squamous cell carcinoma (ESCC)<\/strong>. The candidate, previously awarded <strong>Breakthrough Therapy Designation (BTD) in China<\/strong> and <strong>Orphan Drug\/Fast Track Designations in the U.S. and EU<\/strong>, has demonstrated <strong>first-in-class (FIC) or best-in-class (BIC) potential<\/strong> across three prior indications, positioning Leads Biolabs to address the significant unmet need in one of China&#8217;s highest-incidence malignancies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Phase<\/strong><\/td><td>Phase II<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Opamtistomig (LBL-024)<\/td><\/tr><tr><td><strong>Format<\/strong><\/td><td>Bispecific antibody (BsAb)<\/td><\/tr><tr><td><strong>Targets<\/strong><\/td><td>PD-L1 (checkpoint inhibition) + 4-1BB (costimulatory activation)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>First-line esophageal squamous cell carcinoma (ESCC)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>First-line (previously untreated) ESCC<\/td><\/tr><tr><td><strong>Milestone<\/strong><\/td><td>First patient dosed (March 2026)<\/td><\/tr><tr><td><strong>Sponsor<\/strong><\/td><td>Nanjing Leads Biolabs (HKG: 9887)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-designations-amp-prior-evidence\">Regulatory Designations &amp; Prior Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Designation<\/th><th>Region<\/th><th>Indication Context<\/th><th>Strategic Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Breakthrough Therapy Designation (BTD)<\/strong><\/td><td>China<\/td><td>NSCLC, SCLC, extrapulmonary NEC<\/td><td>Accelerated NMPA review pathway; validation of clinical significance<\/td><\/tr><tr><td><strong>Orphan Drug Designation (ODD)<\/strong><\/td><td>U.S.<\/td><td>Rare cancers (SCLC, NEC)<\/td><td>7-year market exclusivity; tax incentives; waiver fees<\/td><\/tr><tr><td><strong>Fast Track Designation<\/strong><\/td><td>U.S.<\/td><td>\u2014<\/td><td>Rolling review; priority FDA engagement<\/td><\/tr><tr><td><strong>Orphan Drug Designation (ODD)<\/strong><\/td><td>European Union<\/td><td>\u2014<\/td><td>10-year market exclusivity; protocol assistance<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Prior Clinical Performance (FIC\/BIC Potential):<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Non-small cell lung cancer (NSCLC):<\/strong> Phase II\/registrational trials ongoing<\/li>\n\n\n\n<li><strong>Small cell lung cancer (SCLC):<\/strong> Registrational-stage development<\/li>\n\n\n\n<li><strong>Extrapulmonary neuroendocrine carcinoma (NEC):<\/strong> Phase II efficacy signals<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-mechanism-of-action-amp-differentiation\">Mechanism of Action &amp; Differentiation<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Function<\/th><th>Therapeutic Synergy<\/th><\/tr><\/thead><tbody><tr><td><strong>PD-L1 Arm<\/strong><\/td><td>Blocks PD-1\/PD-L1 interaction; restores T-cell recognition of tumor cells<\/td><td>Checkpoint inhibition reverses immune evasion<\/td><\/tr><tr><td><strong>4-1BB Arm<\/strong><\/td><td>Costimulatory receptor activation on T-cells; enhances proliferation, survival, and effector function<\/td><td>Conditional activation only when PD-L1 engagement occurs \u2192 tumor-localized immune stimulation<\/td><\/tr><tr><td><strong>Bispecific Format<\/strong><\/td><td>Dual targeting in single molecule<\/td><td>Reduced systemic 4-1BB agonism toxicity vs. monotherapy; enhanced tumor-specific immune activation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Competitive Positioning vs. Standard of Care:<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Opamtistomig<\/th><th>Chemo + PD-1 (Current 1L ESCC)<\/th><th>Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Mechanism<\/strong><\/td><td>Dual checkpoint + costimulation<\/td><td>Chemotherapy + single checkpoint<\/td><td>Potential for superior ORR and durability<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Conditional 4-1BB activation<\/td><td>Chemo-related myelosuppression<\/td><td>Reduced hematologic toxicity<\/td><\/tr><tr><td><strong>Efficacy Signal<\/strong><\/td><td>FIC\/BIC potential in prior tumors<\/td><td>Modest survival benefit<\/td><td>Potential for paradigm shift in ESCC immunotherapy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-value\">Market Context &amp; Strategic Value<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Implication<\/th><\/tr><\/thead><tbody><tr><td><strong>ESCC Burden<\/strong><\/td><td>China accounts for <strong>50%+ of global ESCC cases<\/strong>; 300,000+ annual diagnoses; 5-year survival &lt;20% in advanced disease<\/td><\/tr><tr><td><strong>Standard of Care Evolution<\/strong><\/td><td>PD-1 + chemotherapy approved (2020-2022); bispecifics represent next-generation immunotherapy<\/td><\/tr><tr><td><strong>First-Line Positioning<\/strong><\/td><td>Front-line ESCC approval would capture largest addressable population; second-line salvage therapy limited efficacy<\/td><\/tr><tr><td><strong>Global Expansion<\/strong><\/td><td>U.S.\/EU ODD\/FTD enables parallel development; potential for simultaneous China-Western registration<\/td><\/tr><tr><td><strong>Valuation Impact<\/strong><\/td><td>HKG: 9887 shares expected to benefit from Phase II milestone; BTD validation supports premium multiples<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-outlook\">Development Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Phase II Design:<\/strong> Single-arm or randomized vs. chemo-PD-1 combination; primary endpoint ORR with PFS\/OS secondary<\/li>\n\n\n\n<li><strong>Biomarker Strategy:<\/strong> PD-L1 expression, TMB, and immune infiltrate analysis to identify responder populations<\/li>\n\n\n\n<li><strong>Combination Potential:<\/strong> Future chemo-PD-1-opamtistomig triplet studies planned<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> China NDA 2027-2028 contingent on Phase II data; U.S. BLA 2028-2029 via ODD\/FTD accelerated track<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and competitive positioning for opamtistomig in esophageal squamous cell carcinoma. Actual results may differ due to trial outcomes, competitive dynamics with PD-1 combinations, and manufacturing scale-up challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030600400_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026030600400_c.\"><\/object><a id=\"wp-block-file--media-5aa0ddf7-a91d-4e69-819a-6bc033335fcc\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030600400_c.pdf\">2026030600400_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2026030600400_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5aa0ddf7-a91d-4e69-819a-6bc033335fcc\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced first patient enrollment in a Phase II&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,4242,1974,28],"class_list":["post-59086","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-hkg-9887","tag-leads-biolabs","tag-multi-specific-antibodies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Leads Biolabs&#039; Opamtistomig Enters Phase II in First-Line Esophageal Cancer \u2013 PD-L1\/4-1BB Bispecific with BTD\/ODD Designations - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced first patient enrollment in a Phase II clinical study evaluating opamtistomig (LBL-024), a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in first-line esophageal squamous cell carcinoma (ESCC). The candidate, previously awarded Breakthrough Therapy Designation (BTD) in China and Orphan Drug\/Fast Track Designations in the U.S. and EU, has demonstrated first-in-class (FIC) or best-in-class (BIC) potential across three prior indications, positioning Leads Biolabs to address the significant unmet need in one of China&#039;s highest-incidence malignancies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59086\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Leads Biolabs&#039; Opamtistomig Enters Phase II in First-Line Esophageal Cancer \u2013 PD-L1\/4-1BB Bispecific with BTD\/ODD Designations\" \/>\n<meta property=\"og:description\" content=\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced first patient enrollment in a Phase II clinical study evaluating opamtistomig (LBL-024), a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in first-line esophageal squamous cell carcinoma (ESCC). The candidate, previously awarded Breakthrough Therapy Designation (BTD) in China and Orphan Drug\/Fast Track Designations in the U.S. and EU, has demonstrated first-in-class (FIC) or best-in-class (BIC) potential across three prior indications, positioning Leads Biolabs to address the significant unmet need in one of China&#039;s highest-incidence malignancies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59086\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T05:11:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-09T05:11:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59086#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59086\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Leads Biolabs&#8217; Opamtistomig Enters Phase II in First-Line Esophageal Cancer \u2013 PD-L1\\\/4-1BB Bispecific with BTD\\\/ODD Designations\",\"datePublished\":\"2026-03-09T05:11:26+00:00\",\"dateModified\":\"2026-03-09T05:11:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59086\"},\"wordCount\":559,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"HKG: 9887\",\"Leads Biolabs\",\"Multi-specific antibodies\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59086#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59086\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59086\",\"name\":\"Leads Biolabs' Opamtistomig Enters Phase II in First-Line Esophageal Cancer \u2013 PD-L1\\\/4-1BB Bispecific with BTD\\\/ODD Designations - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-03-09T05:11:26+00:00\",\"dateModified\":\"2026-03-09T05:11:27+00:00\",\"description\":\"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced first patient enrollment in a Phase II clinical study evaluating opamtistomig (LBL-024), a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in first-line esophageal squamous cell carcinoma (ESCC). The candidate, previously awarded Breakthrough Therapy Designation (BTD) in China and Orphan Drug\\\/Fast Track Designations in the U.S. and EU, has demonstrated first-in-class (FIC) or best-in-class (BIC) potential across three prior indications, positioning Leads Biolabs to address the significant unmet need in one of China's highest-incidence malignancies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59086#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59086\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59086#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Leads Biolabs&#8217; Opamtistomig Enters Phase II in First-Line Esophageal Cancer \u2013 PD-L1\\\/4-1BB Bispecific with BTD\\\/ODD Designations\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Leads Biolabs' Opamtistomig Enters Phase II in First-Line Esophageal Cancer \u2013 PD-L1\/4-1BB Bispecific with BTD\/ODD Designations - Insight, China&#039;s Pharmaceutical Industry","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced first patient enrollment in a Phase II clinical study evaluating opamtistomig (LBL-024), a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in first-line esophageal squamous cell carcinoma (ESCC). The candidate, previously awarded Breakthrough Therapy Designation (BTD) in China and Orphan Drug\/Fast Track Designations in the U.S. and EU, has demonstrated first-in-class (FIC) or best-in-class (BIC) potential across three prior indications, positioning Leads Biolabs to address the significant unmet need in one of China's highest-incidence malignancies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59086","og_locale":"en_US","og_type":"article","og_title":"Leads Biolabs' Opamtistomig Enters Phase II in First-Line Esophageal Cancer \u2013 PD-L1\/4-1BB Bispecific with BTD\/ODD Designations","og_description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced first patient enrollment in a Phase II clinical study evaluating opamtistomig (LBL-024), a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in first-line esophageal squamous cell carcinoma (ESCC). The candidate, previously awarded Breakthrough Therapy Designation (BTD) in China and Orphan Drug\/Fast Track Designations in the U.S. and EU, has demonstrated first-in-class (FIC) or best-in-class (BIC) potential across three prior indications, positioning Leads Biolabs to address the significant unmet need in one of China's highest-incidence malignancies.","og_url":"https:\/\/flcube.com\/?p=59086","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-09T05:11:26+00:00","article_modified_time":"2026-03-09T05:11:27+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59086#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59086"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Leads Biolabs&#8217; Opamtistomig Enters Phase II in First-Line Esophageal Cancer \u2013 PD-L1\/4-1BB Bispecific with BTD\/ODD Designations","datePublished":"2026-03-09T05:11:26+00:00","dateModified":"2026-03-09T05:11:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59086"},"wordCount":559,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","HKG: 9887","Leads Biolabs","Multi-specific antibodies"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59086#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59086","url":"https:\/\/flcube.com\/?p=59086","name":"Leads Biolabs' Opamtistomig Enters Phase II in First-Line Esophageal Cancer \u2013 PD-L1\/4-1BB Bispecific with BTD\/ODD Designations - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-03-09T05:11:26+00:00","dateModified":"2026-03-09T05:11:27+00:00","description":"Nanjing Leads Biolabs Co., Ltd. (HKG: 9887) announced first patient enrollment in a Phase II clinical study evaluating opamtistomig (LBL-024), a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in first-line esophageal squamous cell carcinoma (ESCC). The candidate, previously awarded Breakthrough Therapy Designation (BTD) in China and Orphan Drug\/Fast Track Designations in the U.S. and EU, has demonstrated first-in-class (FIC) or best-in-class (BIC) potential across three prior indications, positioning Leads Biolabs to address the significant unmet need in one of China's highest-incidence malignancies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59086#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59086"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59086#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Leads Biolabs&#8217; Opamtistomig Enters Phase II in First-Line Esophageal Cancer \u2013 PD-L1\/4-1BB Bispecific with BTD\/ODD Designations"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59086"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59086\/revisions"}],"predecessor-version":[{"id":59088,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59086\/revisions\/59088"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}